Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios

Lancet

Volumn 357, Issue 9266, 2001, Pages 1438-1440

  Montaner, J ^a   Hill, A ^b   Acosta, E ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIINFECTIVE AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

BLOOD LEVEL; CELL TYPE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SHORT SURVEY; VIRUS REPLICATION;

EID: 0035810636     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04577-3     Document Type: Note

References (19)

1. Levison M.E. Pharmacodynamics of antibacterial drugs. Infect Dis Clin North Am. 14:2000;281-291.
2. Hirsch M.S., Conway B., D'Aqula R.T., et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA. 279:1998;1984-1991.
3. Durant J., Clevenbergh P., Garraffo R., et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS. 14:2000;1333-1339.
4. Condra J.H., Petropoulos C.J., Ziermann R., Schleif W.A., Shivaprakask M., Emini E.A. Drug resistance and predicted virologic responses to human immundeficiency virus type I protease inhibitor therapy. J Infect Dis. 182:2000;758-765.
5. Avanti Steering Committee. Analysis of HIV-1 clinical trials: statistical magic? Lancet 1999; 353: 2061-64.
6. th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology (abstr 2209)1999.
7. Falloon J., Piscitelli S., Vogel S., et al. Combination therapy with amprenavir, abacavir and efavirenz in human immunodeficiency virus (HIV)- infected patients failing a protease-inhibitor based regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis. 30:2000;313-318.
8. Molla A., Vasavanonda S., Kumar G., et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology. 250:1998;255-262.
9. Kilby J.M., Sfakianos G., Gizzi N., et al. Safety and pharmacokinetics of once-daily regimens of soft-Gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother. 44:2000;2672-2678.
10. th Conference on Retroviruses and Opportunistic Infections. Chicago, 1999.
11. Hsyu P.H., Lewis R.H., Tran J.H., et al. Pharmacokinetics (PK) of nelfinavir (NFV) after once-daily dosing in combination with mini-doses of ritonavir (RTV) in healthy subjects. In: Programme and abstracts of the XIII International AIDS Conference. Durban, 2000.
12. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology 2000.
13. th Conference on Retroviruses and Opportunistic Infection. January 30-February 2, 2000.
14. Drusano G.L., D'Argenzio D.Z., Symonds W., et al. Nucleoside1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother. 42:1998;2153-2159.
15. Nascimbeni M., Lamotte C., Peytavin G., et al. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother. 43:1999;2629-2634.
16. Hennessy M., Clarke S., Mulcahy F., et al. Intracellular indinavir pharmacokinetics in HIV positive patients. AIDS. 14:(suppl 4):2000;S97. (abstr).
17. Barry M., Gibbons S., Back D., et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet. 32:1997;194-209.
18. th European ISSX meeting. Gothenburg, Sweden, 30 June 1997, (abstr).
19. Gieschke R., Fotteler B., Buss N., Steimer J.L. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet. 37:1999;75-86.